ENVIDA BIOTECHNOLOGIES

Envida Biotechnologies develops synthetic, bioresorbable polymers for drug delivery, anti-adhesions and tissue regeneration. Adhesions are potentially life threatening post-surgical complications that occur in 95% of major surgical procedures. US healthcare costs in 2014 for adhesion treatment were $2 billion. Envida Biotechnologies has developed a novel adhesion limiting technology, Endurafilm™, a bioresorbable adhesion barrier made from a proprietary and biocompatible polymer. Endurafilm™ exhibits superior adhesion limiting properties and causes fewer post-surgical complications than current devices.